Allos Therapeutics, Inc. to Hold Post Advisory Committee Conference Call

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee meeting for FOLOTYN™ (pralatrexate). FOLOTYN is the Company’s investigational selective antifolate that is currently being evaluated by the FDA for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.